Gerilimzumab

Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6) . Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis[1].

Product Specifications

Product Name Alternative

ARGX-109; GB224; RYI-008

UNSPSC

12352100

Target

Interleukin Related

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

References & Citations

[1]Yan D, et al. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose-escalation study. Expert Opin Investig Drugs. 2023 Feb;32 (2) :161-170.